US Patent

US7683051 — Crystalline polymorph of bazedoxifene acetate

Method of Use · Assigned to Wyeth LLC · Expires 2027-03-10 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a crystalline polymorph of bazedoxifene acetate and compositions, preparations, and uses thereof.

USPTO Abstract

The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof.

Drugs covered by this patent

Duavee (Bazedoxifene Acetate) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-594`	—	Duavee

Patent Metadata

Patent number: US7683051
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-10
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.